Modality
ERT
MOA
KRASG12Di
Target
DLL3
Pathway
JAK/STAT
SCLC
Development Pipeline
Preclinical
~May 2024
→ ~Aug 2025
Phase 1
Nov 2025
→ Dec 2031
Phase 1Current
NCT06057073
581 pts·SCLC
2025-11→2031-12·Active
581 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-12-125.7y awayInterim· SCLC
Trial Timeline
Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1
Active
Catalysts
Interim
2031-12-12 · 5.7y away
SCLC
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06057073 | Phase 1 | SCLC | Active | 581 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 |